TITLE

Mucosal Immunity in Healthy Adults after Parenteral Vaccination with Outer-Membrane Vesicles from Neisseria meningitidis Serogroup B

AUTHOR(S)
Davenport, Victoria; Groves, Eleanor; Horton, Rachel E.; Hobbs, Christopher G.; Guthrie, Terry; Findlow, Jamie; Borrow, Ray; Næss, Lisbeth M.; Oster, Philipp; Heyderman, Robert S.; Williams, Neil A.
PUB. DATE
September 2008
SOURCE
Journal of Infectious Diseases;9/1/2008, Vol. 198 Issue 5, p731
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Nasopharyngeal carriage of meningococcus or related species leads to protective immunity in adolescence or early adulthood. This natural immunity is associated with mucosal and systemic T cell memory. Whether parenteral Neisseria meningitidis serogroup B (MenB) vaccination influences natural mucosal immunity is unknown. Objectives. To determine whether parenteral MenB vaccination affects mucosal immunity in young adults and whether this immunity differs from that induced in the blood. Methods. Otherwise healthy volunteers were immunized with MenB outer membrane vesicle vaccine before and after routine tonsillectomy. Mucosal and systemic immunity were assessed in 9 vaccinees and 12 unvaccinated control subjects by measuring mononuclear cell proliferation, cytokine production, Th1/Th2 surface marker expression, and antibody to MenB antigens. Results. Parenteral vaccination induced a marked increase in systemic T cell immunity against MenB and a Th1 bias. In contrast, although mucosal T cell proliferation in response to MenB neither increased nor decreased following vaccination, mononuclear cell interferon γ, interleukin (IL)-5, and IL-10 production increased, and the Th1/Th2 profile lost its Th1 bias. Conclusions. Parenteral MenB vaccination selectively reprograms preexisting naturally acquired mucosal immunity. As new-generation protein-based MenB vaccine candidates undergo evaluation, the impact of these vaccines on mucosal immunity in both adults and children will need to be addressed.
ACCESSION #
33773105

 

Related Articles

  • New Pneumococcal Vaccine in High-Risk Children. Walling, Anne D. // American Family Physician;3/15/2004, Vol. 69 Issue 6, p1529 

    Presents the results of a study which examined the effectiveness of pneumococcal vaccine in high-risk children to pneumococcal disease in the U.S. Administration of control vaccine for Neisseria meningitis; Dosage of vaccine in community groups; Efficiency of pneumococcal vaccine conjugate PnCRM7.

  • Bacterial meningitis: the impact of vaccination. Makwana, Nick; Riordan, F. Andrew I. // CNS Drugs;2007, Vol. 21 Issue 5, p355 

    Acute bacterial meningitis remains an important cause of morbidity and mortality in children. Children <2 years of age are particularly susceptible to infection with encapsulated bacteria due to their immature response to polysaccharide antigens. Conjugate vaccines, which induce T cell memory,...

  • MCV4 not recommended for children aged 2 to 10 years.  // Infectious Diseases in Children;Apr2008, Vol. 21 Issue 4, p28 

    The article reports that the routine universal vaccination against meningococcal disease for children aged 2 to 10 years is not recommended by a working group for the Advisory Committee on Immunization Practices (ACIP) in the U.S. Carol Baker, a professor pediatrics, has stressed the need to...

  • Children in care missing out on jabs.  // Community Care;2/20/2003, Issue 1460, p15 

    Presents information on the study of immunization status of all children in several health districts in Great Britain. Percentage of children in public care who did not receive meningococcal C vaccine; Percentage of children in public care who moved placement more than three times in 2001.

  • Routine meningococcal vax warranted among US adolescents.  // PharmacoEconomics & Outcomes News;2/25/2006, Issue 497, p8 

    Discusses research on the cost effectiveness of routine vaccination against meningococcal infections in U.S. adolescents. Reference to a study by L. Coudeville et al, presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy held in December 2005; Conjugate vaccine...

  • Effectiveness Analyses May Underestimate Protection of Infants after Group C Meningococcal Immunization. Vu, David M.; Kelly, Dominic; Heath, Paul T.; McCarthy, Noel D.; Pollard, Andrew J.; Granoff, Dan M. // Journal of Infectious Diseases;7/15/2006, Vol. 194 Issue 2, p231 

    Background. Group C meningococcal conjugate-vaccine effectiveness in the United Kingdom declines from ∼90% in the first year to 0% between 1 and 4 years after immunization in infants immunized at 2, 3, and 4 months of age and to 61% in toddlers given a single dose. Confidence intervals are...

  • Mengivac (A+C).  // Royal Society of Medicine: Medicines;2002, p351 

    The article presents information on the Mengivac (A+C) which is a proprietary, prescription-only preparation of a vaccine that is used to give protection against the organism meningococcus Neisseria meningitidis groups A and C, which can cause serious infections such as meningitis. It is...

  • Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany. Elias, Johannes; Schouls, Leo M.; De Pol, Ingrid van; Keijzers, Wendy C.; Martin, Diana R.; Glennie, Anne; Oster, Philipp; Frosch, Matthias; Vogel, Ulrich; Van der Ende, Arie // Emerging Infectious Diseases;Mar2010, Vol. 16 Issue 3, p464 

    Emergence of serogroup B meningococci of clonal complex sequence type (ST) 41/44 can cause high levels of disease, as exemplified by a recent epidemic in New Zealand. Multiplication of annual incidence rates (3.1 cases/100,000 population) of meningococcal disease in a defined German region, the...

  • The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement. Lewis, Lisa A.; Ngampasutadol, Jutamas; Wallace, Ruth; Reid, Jane E. A.; Vogel, Ulrich; Ram, Sanjay // PLoS Pathogens;Jul2010, Vol. 6 Issue 7, p1 

    Complement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the alternative complement pathway inhibitor factor H (fH) to fH-binding protein (fHbp) is one mechanism meningococci employ to limit complement activation on the bacterial surface. fHbp is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics